1 / 10

Tenofovir

Tenofovir. CAPRISA 004. 51%. 39%. HSV-2. HIV-1. 1% tenofovir vaginal gel. “Life is really simple, but we insist on making it complicated.”  Confucius . Coinfection of human lymphoid tissue ex vivo. HSV and other viruses. Recto-sigmoid. HIV-1. 3. HSV-2 G replication

ellard
Télécharger la présentation

Tenofovir

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Tenofovir

  2. CAPRISA 004 51% 39% HSV-2 HIV-1 1% tenofovir vaginal gel

  3. “Life is really simple, but we insist on making it complicated.”  Confucius

  4. Coinfection of human lymphoid tissue ex vivo HSV and other viruses Recto-sigmoid HIV-1

  5. 3 HSV-2G replication (log10 copies/mL) 2 1 0 HSV-2G HIV-1LAI.04 Tenofovir 200 μM • + + + + • - + + • - + - + untreated tenofovir Tenofovir suppresses HSV-2 in the presence of HIV-1 Tenofovir 200 μM HIV-1 p24 (10-3/mL)

  6. Tenofovir Oral Local

  7. Tenofovir Tenofovir-diphosphate IC50 =4.3 µM IC50 =1.3 µM suppression suppression HIV-1 RT HSV DNA polymerase

  8. Acyclovir HCV HSV OTHER HIV Tenofovir

  9. CONCLUSIONS • Tenofovir is a dual-targeted drug that suppresses both HIV-1 and HSV replication. • Tenofovir at concentrations generated during oral drug administration that may (or may not) inhibits HIV transmission are substantially lower than those necessary to inhibit herpes-simplex viruses. • In general, these findings argue that “marginal” antiviral activities of a variety of existing drugs should be revisited to test for possibly missed antiviral activities since in topical applications these drugs may constitute new microbicides with dual or multiple antiviral properties.

  10. Andrea Lisco Christophe Vanpouille, Andrea Introini NICHD, NIH Graciela Andrei, Robert Snoeck, Joost van den Oord, Jan BalzariniRega Institute Emanuela Balestra, Carlo-Federico Perno University of Roma Tor Vergata, Tomas Cihlar Gilead Sciences, Inc.

More Related